A
Andrew J. Ahmann
Researcher at Oregon Health & Science University
Publications - 73
Citations - 7373
Andrew J. Ahmann is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 34, co-authored 66 publications receiving 6145 citations.
Papers
More filters
Journal ArticleDOI
Management of diabetes and hyperglycemia in hospitals.
Stephen Clement,Susan S. Braithwaite,Michelle F. Magee,Andrew J. Ahmann,Elizabeth P. Smith,Rebecca G. Schafer,Irl B. Hirsch +6 more
TL;DR: The purpose of this technical review is to evaluate the evidence relating to the management of hyperglycemia in hospitals, with particular focus on the issue of glycemic control and its possible impact on hospital outcomes.
Journal ArticleDOI
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Richard M. Bergenstal,William V. Tamborlane,Andrew J. Ahmann,John B. Buse,George Dailey,Stephen N. Davis,Carol Joyce,Tim Peoples,Bruce A. Perkins,John B. Welsh,Steven M. Willi,Michael A. Wood +11 more
TL;DR: In both adults and children with inadequately controlled type 1 diabetes, sensor-augmented pump therapy resulted in significant improvement in glycated hemoglobin levels, as compared with injection therapy.
Journal ArticleDOI
Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial.
Roy W. Beck,Tonya D Riddlesworth,Katrina J. Ruedy,Andrew J. Ahmann,Richard M. Bergenstal,Stacie Haller,Craig Kollman,Davida F. Kruger,Janet B. McGill,William H. Polonsky,Elena Toschi,Howard Wolpert,David Price +12 more
TL;DR: Among adults with type 1 diabetes who used multiple daily insulin injections, the use of CGM compared with usual care resulted in a greater decrease in HbA1c level during 24 weeks.
Journal ArticleDOI
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Richard M. Bergenstal,David C. Klonoff,Satish K. Garg,Bruce W. Bode,Melissa Meredith,Robert H. Slover,Andrew J. Ahmann,John B. Welsh,Scott W. Lee,Francine R. Kaufman +9 more
TL;DR: This study showed that over a 3-month period the use of sensor-augmented insulin-pump therapy with the threshold-suspend feature reduced nocturnal hypoglycemia, without increasing glycated hemoglobin values.
Journal ArticleDOI
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial*
Andrew J. Ahmann,Matthew Capehorn,Guillaume Charpentier,Francesco Dotta,Elena Henkel,Ildiko Lingvay,Anders G. Holst,Miriam Annett,Vanita R. Aroda +8 more
TL;DR: Semaglutide 1.0mg was superior to exenatide ER 2.0 mg in improving glycemic control and reducing body weight after 56 weeks of treatment; the drugs had comparable safety profiles, indicating that semaglUTide treatment is highly effective for subjects with type 2 diabetes who are inadequately controlled on oral antidiabetic drugs.